Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar 15;23(3):600-7.
doi: 10.1021/tx900348v.

In silico studies of polyaromatic hydrocarbon inhibitors of cytochrome P450 enzymes 1A1, 1A2, 2A6, and 2B1

Affiliations

In silico studies of polyaromatic hydrocarbon inhibitors of cytochrome P450 enzymes 1A1, 1A2, 2A6, and 2B1

Jayalakshmi Sridhar et al. Chem Res Toxicol. .

Abstract

A computational study was undertaken to understand the nature of binding and the structural features that play a significant role in the binding of arylacetylene molecules to cytochrome P450 enzymes 1A1, 1A2, 2A6, and 2B1. Nine polycyclic arylacetylenes determined to be mechanism-based P450 enzyme inhibitors were studied. The lack of polar substituents in these compounds causes them to be incapable of hydrogen bonding to the polar protein residues. The four P450 enzymes of interest all have phenylalanine residues in the binding pocket for potential pi-pi interactions with the aromatic rings of the inhibitors. The inhibition potency of these arylacetylenes toward P450s 1A1 and 2B1 showed a dependence on the proximity of the inhibitor's triple bond to the prosthetic heme Fe of the enzyme. In P450 enzyme 1A2, the inhibitor's potency showed more dependence on the pi-pi interactions of the inhibitor's ring systems with the phenylalanine residues of the protein, with the proximity of the inhibitor triple bond to the heme Fe weighing in as the second most important factor. The results suggest that maximizing the pi-pi interactions with phenylalanine residues in the binding pocket and optimum proximity of the acetylene moiety to the heme Fe will provide for a substantial increase in the potency of the polyaromatic hydrocarbon mechanism-based inhibitors. A fine balance of these two aspects of binding coupled with attention to supplementing hydrophobic interactions could address potency and selectivity issues for these inhibitors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
3D structures of P450s 1A1 (A) and 2B1 (B) obtained from homology modeling. The protein is shown as a ribbon model and the Heme residue is depicted as stick model.
Figure 2
Figure 2
Structures of arylacetylene inhibitors used for the study
Figure 3
Figure 3
Depicts binding pockets of P450 enzymes 1A1 (A), 1A2 (B), 2A6 (C) and 2B1 (D) with heme and Phenylalanine residues as stick models showing Gaussian contact molecular surfaces in green dots.
Figure 4
Figure 4
Illustrates the π–π interactions between the protein and the ligand and the proximity of the triple bond to the heme Fe atom for the representative molecule 1EP docked in the binding pockets of P45 enzymes 1A1 (A), 1A2 (B) and 2B1 (C). The residues and inhibitor are shown as stick models.
Figure 5
Figure 5
(A), (B), and (C) Relationship between the inhibitor concentration and Heme-C distance for P450 enzymes 1A1, 1A2 and 2B1; (D), (E), and (F) Relationship between the inhibitor concentration and distance between centroids of aromatic rings of Phenylalanine residues and inhibitor for P450 enzymes 1A1, 1A2 and 2B1.
Figure 6
Figure 6
(A) Represents binding modes of most potent inhibitors 1MEP and 2EPHEN for P450 enzyme 1A1; (B) represents binding modes of most potent inhibitor 1MEP for P450 enzyme 1A2. All interacting residues and the inhibitors are shown as stick models.

Similar articles

Cited by

References

    1. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996;6:1–42. - PubMed
    1. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 1993;12:1–51. - PubMed
    1. Guengerich FP. Cytochrome P450: What Have We Learned and What Are the Future Issues? Drug Metabol Rev. 2004;36:159–197. - PubMed
    1. Agundez JA. Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab. 2004;5:211–224. - PubMed
    1. Shimada T, Oda Y, Gillam EM, Guengerich FP, Inoue K. Metabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and P450 1B1 allelic variants and other human cytochromes P450 in Salmonella typhimurium NM2009. Drug Metab Dispos. 2001;29:1176–1182. - PubMed

Publication types

MeSH terms

Substances